Nrf2-related gene expression is impaired during a glucose challenge in type II diabetic rat hearts.
Angiotensin II Type 1 Receptor Blockers
/ pharmacology
Animals
Antioxidants
/ pharmacology
Diabetes Mellitus, Type 2
/ genetics
Gene Expression Regulation
/ drug effects
Glucose
/ metabolism
Glutathione
/ biosynthesis
Heart
/ drug effects
Humans
Insulin Resistance
/ genetics
NF-E2-Related Factor 2
/ genetics
Oxidants
/ pharmacology
Oxidative Stress
/ genetics
Rats
Receptor, Angiotensin, Type 1
/ genetics
Renin-Angiotensin System
/ drug effects
Signal Transduction
/ drug effects
AT1
GSH
Hyperglycemia
Mitochondrial dysfunction
Nrf2
Journal
Free radical biology & medicine
ISSN: 1873-4596
Titre abrégé: Free Radic Biol Med
Pays: United States
ID NLM: 8709159
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
31
07
2018
revised:
21
09
2018
accepted:
03
10
2018
pubmed:
15
10
2018
medline:
18
12
2019
entrez:
15
10
2018
Statut:
ppublish
Résumé
Diabetic hearts are susceptible to damage from inappropriate activation of the renin angiotensin system (RAS) and hyperglycemic events both of which contribute to increased oxidant production. Prolonged elevation of oxidants impairs mitochondrial enzyme function, further contributing to metabolic derangement. Nuclear factor erythriod-2-related factor 2 (Nrf2) induces antioxidant genes including those for glutathione (GSH) synthesis following translocation to the nucleus. We hypothesized that an acute elevation in glucose impairs Nrf2-related gene expression in diabetic hearts, while AT1 antagonism would aid in Nrf2-mediated antioxidant production and energy replenishment. We used four groups (n = 6-8/group) of 25-week-old rats: 1) LETO (lean strain-control), 2) type II diabetic OLETF, 3) OLETF + angiotensin receptor blocker (ARB; 10 mg olmesartan/kg/d × 8 wks), and 4) ARBM (4 weeks on ARB, 4 weeks off) to study the effects of acutely elevated glucose on cardiac mitochondrial function and Nrf2 signaling in the diabetic heart. Animals were gavaged with a glucose bolus (2 g/kg) and groups were dissected at T0, T180, and T360 minutes. Nrf2 mRNA was 32% lower in OLETF rats compared to LETO and remained suppressed in response to glucose. LETO Nrf2 mRNA increased 25% at T360 in response to glucose while no changes were observed in diabetic hearts. GCLC and GCLM mRNA decreased in diabetic hearts 33% and 44% respectively and remained suppressed in response to glucose while ARB treatment increased GCLM transcripts 90% at T180. These data illustrate that during T2DM and in response to glucose, cardiac Nrf2's adaptive response to environmental stressors such as glucose is impaired in diabetic hearts and that ARB treatment may aid Nrf2's impaired dynamic response.
Identifiants
pubmed: 30316779
pii: S0891-5849(18)31281-4
doi: 10.1016/j.freeradbiomed.2018.10.405
pii:
doi:
Substances chimiques
Angiotensin II Type 1 Receptor Blockers
0
Antioxidants
0
NF-E2-Related Factor 2
0
Nfe2l2 protein, rat
0
Oxidants
0
Receptor, Angiotensin, Type 1
0
Glutathione
GAN16C9B8O
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
306-317Subventions
Organisme : NIMHD NIH HHS
ID : T37 MD001480
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.